Skip to content

Edwards Lifesciences

NYSE: EW · USD

Edwards Lifesciences financials

6 charts

Revenue

USD millions

$1,741M
Edwards Lifesciences Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2010 Q2$365.2M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$348.9M; −4.5% vs FY 2010 Q2
FY 2010 Q4$392.4M; +12.5% vs FY 2010 Q3
FY 2011 Q1$404.5M; +3.1% vs FY 2010 Q4
FY 2011 Q2$431.2M; +6.6% vs FY 2011 Q1
FY 2011 Q3$412.7M; −4.3% vs FY 2011 Q2
FY 2011 Q4$430.2M; +4.2% vs FY 2011 Q3
FY 2012 Q1$459.2M; +6.7% vs FY 2011 Q4
FY 2012 Q2$482M; +5.0% vs FY 2012 Q1
FY 2012 Q3$447.9M; −7.1% vs FY 2012 Q2
FY 2012 Q4$510.5M; +14.0% vs FY 2012 Q3
FY 2013 Q1$496.7M; −2.7% vs FY 2012 Q4
FY 2013 Q2$517.2M; +4.1% vs FY 2013 Q1
FY 2013 Q3$495.6M; −4.2% vs FY 2013 Q2
FY 2013 Q4$536M; +8.2% vs FY 2013 Q3
FY 2014 Q1$522.4M; −2.5% vs FY 2013 Q4
FY 2014 Q2$575.1M; +10.1% vs FY 2014 Q1
FY 2014 Q3$607.4M; +5.6% vs FY 2014 Q2
FY 2014 Q4$618M; +1.7% vs FY 2014 Q3
FY 2015 Q1$590.3M; −4.5% vs FY 2014 Q4
FY 2015 Q2$616.8M; +4.5% vs FY 2015 Q1
FY 2015 Q3$615.5M; −0.2% vs FY 2015 Q2
FY 2015 Q4$671.1M; +9.0% vs FY 2015 Q3
FY 2016 Q1$697.3M; +3.9% vs FY 2015 Q4
FY 2016 Q2$759.3M; +8.9% vs FY 2016 Q1
FY 2016 Q3$739.4M; −2.6% vs FY 2016 Q2
FY 2016 Q4$767.7M; +3.8% vs FY 2016 Q3
FY 2017 Q1$883.5M; +15.1% vs FY 2016 Q4
FY 2017 Q2$841.8M; −4.7% vs FY 2017 Q1
FY 2017 Q3$821.5M; −2.4% vs FY 2017 Q2
FY 2017 Q4$888.5M; +8.2% vs FY 2017 Q3
FY 2018 Q1$894.8M; +0.7% vs FY 2017 Q4
FY 2018 Q2$943.7M; +5.5% vs FY 2018 Q1
FY 2018 Q3$906.6M; −3.9% vs FY 2018 Q2
FY 2018 Q4$977.7M; +7.8% vs FY 2018 Q3
FY 2019 Q1$993M; +1.6% vs FY 2018 Q4
FY 2019 Q2$1,086.9M; +9.5% vs FY 2019 Q1
FY 2019 Q3$1,094M; +0.7% vs FY 2019 Q2
FY 2019 Q4$1,174.1M; +7.3% vs FY 2019 Q3
FY 2020 Q1$1,128.7M; −3.9% vs FY 2019 Q4
FY 2020 Q2$925M; −18.0% vs FY 2020 Q1
FY 2020 Q3$1,140.9M; +23.3% vs FY 2020 Q2
FY 2020 Q4$1,191.7M; +4.5% vs FY 2020 Q3
FY 2021 Q1$1,216.6M; +2.1% vs FY 2020 Q4
FY 2021 Q2$1,376M; +13.1% vs FY 2021 Q1
FY 2021 Q3$1,310.2M; −4.8% vs FY 2021 Q2
FY 2021 Q4$1,329.7M; +1.5% vs FY 2021 Q3
FY 2022 Q1$1,341.2M; +0.9% vs FY 2021 Q4
FY 2022 Q2$1,373.9M; +2.4% vs FY 2022 Q1
FY 2022 Q3$1,319M; −4.0% vs FY 2022 Q2
FY 2022 Q4$1,348.3M; +2.2% vs FY 2022 Q3
FY 2023 Q1$1,459.6M; +8.3% vs FY 2022 Q4
FY 2023 Q2$1,530.2M; +4.8% vs FY 2023 Q1
FY 2023 Q3$1,480.9M; −3.2% vs FY 2023 Q2
FY 2023 Q4$1,266.4M; −14.5% vs FY 2023 Q3
FY 2024 Q1$1,598.2M; +26.2% vs FY 2023 Q4
FY 2024 Q2$1,385.9M; −13.3% vs FY 2024 Q1
FY 2024 Q3$1,354.4M; −2.3% vs FY 2024 Q2
FY 2024 Q4$1,385.8M; +2.3% vs FY 2024 Q3
FY 2025 Q1$1,412.7M; +1.9% vs FY 2024 Q4
FY 2025 Q2$1,532.2M; +8.5% vs FY 2025 Q1
FY 2025 Q3$1,553.1M; +1.4% vs FY 2025 Q2
FY 2025 Q4$1,569.6M; +1.1% vs FY 2025 Q3
FY 2026 Q1$1,648.6M; +5.0% vs FY 2025 Q4
FY 2026 Q2$1,741M; +5.6% vs FY 2026 Q1
Jun 30, 2010 through Sep 25, 2026

Free cash flow

USD millions

$585M
Edwards Lifesciences Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2010 Q2$32.3M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$80M; +147.7% vs FY 2010 Q2
FY 2010 Q4$72.3M; −9.6% vs FY 2010 Q3
FY 2011 Q1$1M; −98.6% vs FY 2010 Q4
FY 2011 Q2$42.1M; +4110.0% vs FY 2011 Q1
FY 2011 Q3$52.5M; +24.7% vs FY 2011 Q2
FY 2011 Q4$110.8M; +111.0% vs FY 2011 Q3
FY 2012 Q1$-48.7M; −144.0% vs FY 2011 Q4
FY 2012 Q2$125.6M; +357.9% vs FY 2012 Q1
FY 2012 Q3$105.6M; −15.9% vs FY 2012 Q2
FY 2012 Q4$70.6M; −33.1% vs FY 2012 Q3
FY 2013 Q1$64.3M; −8.9% vs FY 2012 Q4
FY 2013 Q2$98.6M; +53.3% vs FY 2013 Q1
FY 2013 Q3$109.6M; +11.2% vs FY 2013 Q2
FY 2013 Q4$91.2M; −16.8% vs FY 2013 Q3
FY 2014 Q1$124.6M; +36.6% vs FY 2013 Q4
FY 2014 Q2$762M; +511.6% vs FY 2014 Q1
FY 2014 Q3$-5.9M; −100.8% vs FY 2014 Q2
FY 2014 Q4$58.7M; +1094.9% vs FY 2014 Q3
FY 2015 Q1$52.5M; −10.6% vs FY 2014 Q4
FY 2015 Q2$151.7M; +189.0% vs FY 2015 Q1
FY 2015 Q3$176.5M; +16.3% vs FY 2015 Q2
FY 2015 Q4$66.3M; −62.4% vs FY 2015 Q3
FY 2016 Q1$79.4M; +19.8% vs FY 2015 Q4
FY 2016 Q2$153.2M; +92.9% vs FY 2016 Q1
FY 2016 Q3$157.8M; +3.0% vs FY 2016 Q2
FY 2016 Q4$137.9M; −12.6% vs FY 2016 Q3
FY 2017 Q1$112.4M; −18.5% vs FY 2016 Q4
FY 2017 Q2$139.7M; +24.3% vs FY 2017 Q1
FY 2017 Q3$268.5M; +92.2% vs FY 2017 Q2
FY 2017 Q4$312M; +16.2% vs FY 2017 Q3
FY 2018 Q1$108.1M; −65.4% vs FY 2017 Q4
FY 2018 Q2$87.4M; −19.1% vs FY 2018 Q1
FY 2018 Q3$257.2M; +194.3% vs FY 2018 Q2
FY 2018 Q4$235.4M; −8.5% vs FY 2018 Q3
FY 2019 Q1$-40.7M; −117.3% vs FY 2018 Q4
FY 2019 Q2$276.6M; +779.6% vs FY 2019 Q1
FY 2019 Q3$361.2M; +30.6% vs FY 2019 Q2
FY 2019 Q4$327.9M; −9.2% vs FY 2019 Q3
FY 2020 Q1$124.8M; −61.9% vs FY 2019 Q4
FY 2020 Q2$122.9M; −1.5% vs FY 2020 Q1
FY 2020 Q3$112.8M; −8.2% vs FY 2020 Q2
FY 2020 Q4$286.8M; +154.3% vs FY 2020 Q3
FY 2021 Q1$194.5M; −32.2% vs FY 2020 Q4
FY 2021 Q2$456.8M; +134.9% vs FY 2021 Q1
FY 2021 Q3$471.2M; +3.2% vs FY 2021 Q2
FY 2021 Q4$283.8M; −39.8% vs FY 2021 Q3
FY 2022 Q1$220.6M; −22.3% vs FY 2021 Q4
FY 2022 Q2$289.1M; +31.1% vs FY 2022 Q1
FY 2022 Q3$250M; −13.5% vs FY 2022 Q2
FY 2022 Q4$213.9M; −14.4% vs FY 2022 Q3
FY 2023 Q1$252.6M; +18.1% vs FY 2022 Q4
FY 2023 Q2$-14.3M; −105.7% vs FY 2023 Q1
FY 2023 Q3$356.2M; +2590.9% vs FY 2023 Q2
FY 2023 Q4$48.3M; −86.4% vs FY 2023 Q3
FY 2024 Q1$-118.8M; −346.0% vs FY 2023 Q4
FY 2024 Q2$286.1M; +340.8% vs FY 2024 Q1
FY 2024 Q3$299.9M; +4.8% vs FY 2024 Q2
FY 2024 Q4$-177.3M; −159.1% vs FY 2024 Q3
FY 2025 Q1$224.4M; +226.6% vs FY 2024 Q4
FY 2025 Q2$240.9M; +7.4% vs FY 2025 Q1
FY 2025 Q3$516.2M; +114.3% vs FY 2025 Q2
FY 2025 Q4$353.5M; −31.5% vs FY 2025 Q3
FY 2026 Q1$-21.1M; −106.0% vs FY 2025 Q4
FY 2026 Q2$585M; +2872.5% vs FY 2026 Q1

Net margin

%

13.89%
Edwards Lifesciences Net margin. Reported fiscal history.
Fiscal period%
FY 2010 Q215.74%
FY 2010 Q313.76%
FY 2010 Q416.51%
FY 2011 Q115.8%
FY 2011 Q213.47%
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q127.86%
FY 2022 Q229.58%
FY 2022 Q326.04%
FY 2022 Q429.55%
FY 2023 Q123.33%
FY 2023 Q220.07%
FY 2023 Q325.99%
FY 2023 Q429.21%
FY 2024 Q122.02%
FY 2024 Q226.43%
FY 2024 Q3226.73%
FY 2024 Q427.83%
FY 2025 Q125.34%
FY 2025 Q221.75%
FY 2025 Q318.74%
FY 2025 Q45.81%
FY 2026 Q123.09%
FY 2026 Q213.89%

P/E

× · TTM · Daily

49.6×
Edwards Lifesciences P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-05-3142.64×2011-12-31
2012-06-2951.59×2011-12-31
2012-07-3150.54×2011-12-31
2012-08-3148.83×2012-06-30
2012-09-2851.34×2012-06-30
2012-10-3141.52×2012-06-30
2012-11-3038.94×2012-09-30
2012-12-3140.46×2012-09-30
2013-01-3140.35×2012-09-30
2013-02-2838.56×2012-09-30
2013-03-2836.87×2012-09-30
2013-04-3028.62×2012-09-30
2013-05-3120.76×2013-03-31
2013-06-2820.99×2013-03-31
2013-07-3122.29×2013-03-31
2013-08-3020.22×2013-06-30
2013-09-3020×2013-06-30
2013-10-3118.73×2013-06-30
2013-11-2918.18×2013-09-30
2013-12-3118.24×2013-09-30
2014-01-3118.06×2013-09-30
2014-02-2819.35×2013-09-30
2014-03-3121.04×2013-12-31
2014-04-3023.11×2013-12-31
2014-05-3028.69×2014-03-31
2014-06-3030.33×2014-03-31
2014-07-3131.89×2014-03-31
2014-08-2914.03×2014-06-30
2014-09-3014.44×2014-06-30
2014-10-3117.09×2014-06-30
2014-11-2818.08×2014-09-30
2014-12-3117.75×2014-09-30
2015-01-3017.47×2014-09-30
2015-02-2717.99×2014-12-31
2015-03-3119.27×2014-12-31
2015-04-3015.98×2015-03-31
2015-05-2916.49×2015-03-31
2015-06-3017.97×2015-03-31
2015-07-3138.05×2015-06-30
2015-08-3135.23×2015-06-30
2015-09-3035.55×2015-06-30
2015-10-3037.3×2015-09-30
2015-11-3038.69×2015-09-30
2015-12-3137.5×2015-09-30
2016-01-2937.13×2015-09-30
2016-02-2938.78×2015-12-31
2016-03-3139.32×2015-12-31
2016-04-2947.34×2015-12-31
2016-05-3141.7×2016-03-31
2016-06-3042.22×2016-03-31
2016-07-2948.48×2016-03-31
2016-08-3147.36×2016-06-30
2016-09-3049.58×2016-06-30
2016-10-3137.64×2016-09-30
2016-11-3032.75×2016-09-30
2016-12-3037.04×2016-09-30
2017-01-3138.05×2016-09-30
2017-02-2837.18×2016-09-30
2017-03-3137.19×2016-09-30
2017-04-2843.36×2016-09-30
2017-05-3145.49×2016-09-30
2017-06-3046.74×2016-09-30
2017-07-3145.53×2016-09-30
2017-08-3144.93×2016-09-30
2017-09-2943.21×2016-09-30
2017-10-3140.41×2016-09-30
2017-11-3046.33×2016-09-30
2017-12-2944.56×2016-09-30
2018-01-3150.04×2016-09-30
2018-02-2852.84×2016-09-30
2018-03-2955.16×2016-09-30
2018-04-3050.35×2016-09-30
2018-05-3154.28×2016-09-30
2018-06-2957.55×2016-09-30
2018-07-3156.31×2016-09-30
2018-08-3157.02×2016-09-30
2018-09-2868.83×2016-09-30
2018-10-3158.35×2016-09-30
2018-11-3064.05×2016-09-30
2018-12-3160.55×2016-09-30
2019-01-3167.37×2016-09-30
2019-02-2849.72×2018-12-31
2019-03-2956.2×2018-12-31
2019-04-3048.82×2019-03-31
2019-05-3147.33×2019-03-31
2019-06-2851.22×2019-03-31
2019-07-3162.28×2019-06-30
2019-08-3064.91×2019-06-30
2019-09-3064.34×2019-06-30
2019-10-3165.35×2019-09-30
2019-11-2967.15×2019-09-30
2019-12-3163.95×2019-09-30
2020-01-3160.27×2019-09-30
2020-02-2841.58×2019-12-31
2020-03-3138.29×2019-12-31
2020-04-3041.56×2020-03-31
2020-05-2942.94×2020-03-31
2020-06-3039.62×2020-03-31
2020-07-3165.41×2020-06-30
2020-08-3171.61×2020-06-30
2020-09-3066.58×2020-06-30
2020-10-3056.97×2020-09-30
2020-11-3066.66×2020-09-30
2020-12-3172.49×2020-09-30
2021-01-2965.62×2020-09-30
2021-02-2664.71×2020-12-31
2021-03-3165.13×2020-12-31
2021-04-3070.86×2021-03-31
2021-05-2871.14×2021-03-31
2021-06-3076.83×2021-03-31
2021-07-3083.29×2021-03-31
2021-08-3150.47×2021-06-30
2021-09-3048.76×2021-06-30
2021-10-2951.61×2021-06-30
2021-11-3045.89×2021-09-30
2021-12-3155.4×2021-09-30
2022-01-3146.69×2021-09-30
2022-02-2847.23×2021-12-31
2022-03-3149.48×2021-12-31
2022-04-2943.27×2022-03-31
2022-05-3141.26×2022-03-31
2022-06-3038.9×2022-03-31
2022-07-2941.13×2022-03-31
2022-08-3138.8×2022-06-30
2022-09-3035.58×2022-06-30
2022-10-3131.01×2022-09-30
2022-11-3033.07×2022-09-30
2022-12-3031.94×2022-09-30
2023-01-3132.83×2022-09-30
2023-02-2834.44×2022-09-30
2023-03-3135.42×2022-09-30
2023-04-2837.66×2022-09-30
2023-05-3136.06×2022-09-30
2023-06-3040.38×2022-09-30
2023-07-3135.13×2022-09-30
2023-08-3132.74×2022-09-30
2023-09-2929.66×2022-09-30
2023-10-3127.28×2022-09-30
2023-11-3028.99×2022-09-30
2023-12-2932.64×2022-09-30
2024-01-3133.59×2022-09-30
2024-02-2936.33×2022-09-30
2024-03-2840.91×2022-09-30
2024-04-3036.25×2022-09-30
2024-05-3137.2×2022-09-30
2024-06-2839.54×2022-09-30
2024-07-3126.99×2022-09-30
2024-08-3029.95×2022-09-30
2024-09-3028.25×2022-09-30
2024-10-3128.69×2022-09-30
2024-11-2930.54×2022-09-30
2024-12-3131.69×2022-09-30
2025-01-3131.02×2022-09-30
2025-02-2830.66×2022-09-30
2025-03-3110.26×2024-12-31
2025-04-3010.68×2024-12-31
2025-05-3011.07×2024-12-31
2025-06-3011.07×2024-12-31
2025-07-3111.22×2024-12-31
2025-08-2911.51×2024-12-31
2025-09-3011×2024-12-31
2025-10-3111.67×2024-12-31
2025-11-2837.11×2025-09-30
2025-12-3136.5×2025-09-30
2026-01-3034.84×2025-09-30
2026-02-2746.85×2025-12-31
2026-03-3143.39×2025-12-31
2026-04-3045.24×2025-12-31
2026-05-2945.81×2026-03-31
2026-06-3047.92×2026-03-31
2026-07-3145.59×2026-03-31
2026-08-3152.16×2026-06-30
2026-09-2549.6×2026-06-30
Mean 40.23×Median 39.44×26% above median

ROIC

% · Annual / TTM

—
Edwards Lifesciences ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q421.61%
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q422.91%
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$220.2M
Edwards Lifesciences capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q213.42% · $15.7MUnavailable86.58% · $101.3MUnavailableUnavailable100% · $117M
FY 2010 Q313.09% · $16.4MUnavailable0.56% · $0.7MUnavailable86.35% · $108.2M100% · $125.3M
FY 2010 Q4100% · $21.7MUnavailable0% · $0MUnavailableUnavailable100% · $21.7M
FY 2011 Q110.51% · $13.9M32.2% · $42.6M57.29% · $75.8MUnavailableUnavailable100% · $132.3M
FY 2011 Q217.13% · $17.2M0% · $0M82.87% · $83.2MUnavailableUnavailable100% · $100.4M
FY 2011 Q315.75% · $19.5M0% · $0M84.25% · $104.3MUnavailableUnavailable100% · $123.8M
FY 2011 Q444.61% · $32.3M0% · $0M55.39% · $40.1MUnavailableUnavailable100% · $72.4M
FY 2012 Q116.74% · $18MUnavailable83.26% · $89.5MUnavailableUnavailable100% · $107.5M
FY 2012 Q228.3% · $21.2MUnavailable71.7% · $53.7MUnavailableUnavailable100% · $74.9M
FY 2012 Q352.66% · $25.7MUnavailable47.34% · $23.1MUnavailableUnavailable100% · $48.8M
FY 2012 Q423.89% · $55.8MUnavailable76.11% · $177.8MUnavailableUnavailable100% · $233.6M
FY 2013 Q17.96% · $23MUnavailable37.27% · $107.7MUnavailable54.78% · $158.3M100% · $289M
FY 2013 Q29.44% · $28.4MUnavailable46.15% · $138.9MUnavailable44.42% · $133.7M100% · $301M
FY 2013 Q311.26% · $37.5MUnavailable68.37% · $227.6MUnavailable20.37% · $67.8M100% · $332.9M
FY 2013 Q43.48% · $20.1MUnavailable3.92% · $22.7MUnavailable92.6% · $535.6M100% · $578.4M
FY 2014 Q13.64% · $14.3MUnavailable76.41% · $300MUnavailable19.94% · $78.3M100% · $392.6M
FY 2014 Q210.58% · $16MUnavailable0.4% · $0.6MUnavailable89.02% · $134.6M100% · $151.2M
FY 2014 Q374.49% · $18.1MUnavailable0.41% · $0.1MUnavailable25.1% · $6.1M100% · $24.3M
FY 2014 Q469.42% · $34.5M30.18% · $15M0.4% · $0.2MUnavailableUnavailable100% · $49.7M
FY 2015 Q117.08% · $20.8MUnavailable82.92% · $101MUnavailableUnavailable100% · $121.8M
FY 2015 Q218.91% · $18.4MUnavailable81.09% · $78.9MUnavailableUnavailable100% · $97.3M
FY 2015 Q399.24% · $26MUnavailable0.76% · $0.2MUnavailableUnavailable100% · $26.2M
FY 2015 Q425.17% · $37.5M7.72% · $11.5M67.11% · $100MUnavailableUnavailable100% · $149M
FY 2016 Q17.45% · $27.7M0% · $0M92.55% · $344.1MUnavailableUnavailable100% · $371.8M
FY 2016 Q250.34% · $37.1M0% · $0M49.66% · $36.6MUnavailableUnavailable100% · $73.7M
FY 2016 Q399.59% · $48.1M0% · $0M0.41% · $0.2MUnavailableUnavailable100% · $48.3M
FY 2016 Q418.34% · $63.2M0% · $0M81.66% · $281.4MUnavailableUnavailable100% · $344.6M
FY 2017 Q12.97% · $15.9M15.32% · $82M81.71% · $437.4MUnavailableUnavailable100% · $535.3M
FY 2017 Q243.09% · $58M2.08% · $2.8M54.83% · $73.8MUnavailableUnavailable100% · $134.6M
FY 2017 Q397.92% · $42.3M0.23% · $0.1M1.85% · $0.8MUnavailableUnavailable100% · $43.2M
FY 2017 Q412.62% · $51.9M26.26% · $108M61.11% · $251.3MUnavailableUnavailable100% · $411.2M
FY 2018 Q195.15% · $43.2M0% · $0M4.85% · $2.2MUnavailableUnavailable100% · $45.4M
FY 2018 Q213.17% · $52.8M0% · $0M86.83% · $348.2MUnavailableUnavailable100% · $401M
FY 2018 Q332.96% · $85.1M0% · $0M67.04% · $173.1MUnavailableUnavailable100% · $258.2M
FY 2018 Q417.48% · $57.6M0% · $0M82.52% · $272MUnavailableUnavailable100% · $329.6M
FY 2019 Q150.9% · $42.2M42.22% · $35M6.88% · $5.7MUnavailableUnavailable100% · $82.9M
FY 2019 Q216.73% · $64.6M16.89% · $65.2M66.38% · $256.3MUnavailableUnavailable100% · $386.1M
FY 2019 Q398.32% · $76.1M0% · $0M1.68% · $1.3MUnavailableUnavailable100% · $77.4M
FY 2019 Q4100% · $71.5M0% · $0M0% · $0MUnavailableUnavailable100% · $71.5M
FY 2020 Q111.79% · $82.2MUnavailable88.21% · $614.8MUnavailableUnavailable100% · $697M
FY 2020 Q292.33% · $108.3MUnavailable7.67% · $9MUnavailableUnavailable100% · $117.3M
FY 2020 Q398.66% · $103.3MUnavailable1.34% · $1.4MUnavailableUnavailable100% · $104.7M
FY 2020 Q499.82% · $113.2MUnavailable0.18% · $0.2MUnavailableUnavailable100% · $113.4M
FY 2021 Q125.94% · $106MUnavailable74.06% · $302.6MUnavailableUnavailable100% · $408.6M
FY 2021 Q238.25% · $69.3MUnavailable61.75% · $111.9MUnavailableUnavailable100% · $181.2M
FY 2021 Q397.12% · $60.7MUnavailable2.88% · $1.8MUnavailableUnavailable100% · $62.5M
FY 2021 Q448.2% · $89.8MUnavailable51.8% · $96.5MUnavailableUnavailable100% · $186.3M
FY 2022 Q115.2% · $72.7MUnavailable84.8% · $405.6MUnavailableUnavailable100% · $478.3M
FY 2022 Q210.82% · $43.1MUnavailable89.18% · $355.1MUnavailableUnavailable100% · $398.2M
FY 2022 Q337.37% · $59.9MUnavailable62.63% · $100.4MUnavailableUnavailable100% · $160.3M
FY 2022 Q47.37% · $68.9MUnavailable92.63% · $866MUnavailableUnavailable100% · $934.9M
FY 2023 Q119.79% · $61.5MUnavailable80.21% · $249.3MUnavailableUnavailable100% · $310.8M
FY 2023 Q286.46% · $47.9MUnavailable13.54% · $7.5MUnavailableUnavailable100% · $55.4M
FY 2023 Q324.07% · $55.3MUnavailable75.93% · $174.4MUnavailableUnavailable100% · $229.7M
FY 2023 Q416.45% · $88.3MUnavailable83.55% · $448.4MUnavailableUnavailable100% · $536.7M
FY 2024 Q199.69% · $65.3MUnavailable0.31% · $0.2MUnavailableUnavailable100% · $65.5M
FY 2024 Q235.07% · $85.4MUnavailable64.93% · $158.1MUnavailableUnavailable100% · $243.5M
FY 2024 Q35.45% · $51.9MUnavailable94.55% · $901MUnavailableUnavailable100% · $952.9M
FY 2024 Q433.22% · $49.8MUnavailable66.78% · $100.1MUnavailableUnavailable100% · $149.9M
FY 2025 Q117.8% · $56MUnavailable82.2% · $258.6MUnavailableUnavailable100% · $314.6M
FY 2025 Q289.96% · $49.3MUnavailable10.04% · $5.5MUnavailableUnavailable100% · $54.8M
FY 2025 Q38.9% · $57.5MUnavailable91.1% · $588.7MUnavailableUnavailable100% · $646.2M
FY 2025 Q470.58% · $97.4MUnavailable29.42% · $40.6MUnavailableUnavailable100% · $138M
FY 2026 Q113.33% · $64.9MUnavailable86.67% · $421.8MUnavailableUnavailable100% · $486.7M
FY 2026 Q230.38% · $66.9MUnavailable69.62% · $153.3MUnavailableUnavailable100% · $220.2M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Edwards Lifesciences.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources